Cholangiocarcinoma (Bile Duct Cancer) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Cholangiocarcinoma, also called bile duct cancer, is a rare form of cancer that arises from the malignant transformation of cells in the bile ducts. There are two main types of cholangiocarcinoma: intrahepatic, which originates in the bile ducts within the liver, and extrahepatic, which occurs in the bile ducts outside the liver. The latter is classified into perihilar and distal bile duct cancer based on location. The signs and symptoms of cholangiocarcinoma include jaundice, dark urine, clay-colored stools, abdominal pain, fever, itchy skin, nausea and vomiting, and unexplained weight loss. It is important to consult a physician if these symptoms are present. The risk factors for cholangiocarcinoma include primary sclerosing cholangitis, chronic ulcerative colitis, bile duct cysts, and infection with the Chinese liver fluke parasite. The staging of cholangiocarcinoma is determined using the TNM system, which assesses the size of the tumor (T), the number of affected lymph nodes (N), and the extent of distant metastasis (M).
·
The incidence of bile duct cancer in the USA
is about 4.4 cases per 100,000 individuals annually.
Thelansis’s “Cholangiocarcinoma (Bile
Duct Cancer) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2022 To 2032" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Cholangiocarcinoma (Bile Duct
Cancer) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Cholangiocarcinoma (Bile Duct Cancer) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Cholangiocarcinoma (Bile Duct Cancer) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment